<DOC>
	<DOCNO>NCT01598337</DOCNO>
	<brief_summary>This protocol design evaluate effect antiplatelets ( Tirafiban Prasugrel ) incidence early intermediate graft patency CABG .</brief_summary>
	<brief_title>The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency</brief_title>
	<detailed_description>Coronary artery bypass graft ( CABG ) surgery commonly use revascularization strategy patient severe coronary artery disease . Saphenous vein graft ( SVGs ) frequently use conduit procedure . Unlike arterial graft , SVGs particularly susceptible occlusive thrombosis first post-operative year , expose patient increase risk death , myocardial infarction , repeat revascularization . This study design evaluate effect antiplatelets ( Tirafiban Prasugrel ) incidence early intermediate graft patency CABG . Patients undergo plan cardiac Computed tomographic angiography ( CTA ) predischarge ( 1 week ) CTA/coronary angiography ( CAG ) 6 month 1 year follow-up . CTA baseline ( predischarge ) follow-up CTA/CAG 6-12 month CABG use evaluate graft patency .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>All comer study patient undergo coronary bypass surgery ( CABG ) randomize one four treatment group Acute myocardial infarction ( AMI ) cardiogenic shock Aortic dissection Mechanical valve . Contraindication antiplatelets aggrastat . Active bleeding high risk bleeding . History hemorrhagic stroke time . Recent history embolic stroke transient ischemic attack ( TIA ) less 3 month . Active peptic ulcer disease ( PUD ) . Liver derangement . Warfarin use . Heparininduced thrombocytopenia ( HIT ) syndrome . Thrombocytopenia ( platelet count &lt; 100,000/mm3 ) , disorder platelet function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>